Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALVAC-HIV vCP300
- Development stage
- Phase 1
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intramuscular
01
Overview
ALVAC-HIV vCP300 is an investigational recombinant viral vector vaccine candidate developed for the prevention of HIV-1 infection. It utilizes a modified, replication-incompetent canarypox virus (ALVAC) vector to express multiple HIV-1 antigens, specifically the envelope glycoprotein gp120, the structural Gag protein, the viral protease, and cytotoxic T-lymphocyte (CTL) epitopes from the Nef and Pol proteins. Developed by the National Institute of Allergy and Infectious Diseases (NIAID) in collaboration with Sanofi Pasteur, vCP300 is designed to induce broad cellular immune responses, particularly CD8+ T-cell activity. In clinical development, it was primarily evaluated in prime-boost strategies where the viral vector prime was followed by a protein subunit boost (such as rgp120/HIV-1 SF2) to elicit both cellular immunity and neutralizing antibodies.
- Other names
- ALVAC-HIV vCP300ALVAC-HIV MN120TMGNP (vCP300)
02
Targets
BCR (Immunoglobulin G B Cell Receptor)Nef (HIV-1 Nef)HIV-1 proteaseγδ TCR (T-cell receptor)Gag (HIV-1 Gag polyprotein)Human immunodeficiency virus type 1 reverse transcriptaseEnv (HIV-1 envelope glycoprotein)PR (Progesterone receptor)
Beyond the preview
Go deeper on ALVAC-HIV vCP300.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALVAC-HIV vCP300.